Iron Sucrose

Iron sucrose injection is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). ( 1 )

12.1 Mechanism of Action Iron sucrose is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

With Approximately 6–18 hours terminal plasma half-life for Iron Sucrose residence kinetics and Complete (~100%) parenteral systemic delivery for Iron Sucrose (20 mg/mL Injection, Solution) bioavailability, Iron Sucrose undergoes phase i/ii hepatic conjugation of iron sucrose coupled with glomerular and tubular renal excretion and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after iron sucrose administration.

Standard adult regimens span 20 mg/mL Injection, Solution, 200 mg/10mL Injection, 20 mg/mL Injection, 50 mg/2.5mL Injection, 50 mg/2.5mL Injection, Solution. Prescribers screen specifically against 4 contraindications; known hypersensitivity to iron sucrose.; known hypersensitivity to iron sucrose., while community micro-logs most frequently note nausea (10.2% of reports), headache (8.8% of reports), dizziness (8.1% of reports).